Neuropathic pain ups resource use, costs in Spain

January 2008
PharmacoEconomics & Outcomes News;1/12/2008, Issue 544, p6
The article focuses on research in Spain which involved several patients with neuropathic pain of broad aetiology and patients who had been referred to pain clinics from primary care providers. Accordingly, drugs, diagnostic procedures and nondrug therapies were the most commonly used healthcare resources in the study. It says that the extra costs originating from drug acquisition noticed in patients primarily managed at pain clinics were offset by lower costs for other components of pain management.


Related Articles

  • The Safest Pain Management Options for Older Adults.  // Healthy Years;Aug2013, Vol. 10 Issue 8, p6 

    The article reveals that the proper treatment for pain in older adults depends on the cause of pain, its intensity, the medicine's side effects and what might really be appropriate for a person. It says that the best approach in treating pain problems is the treatment and cure of the underlying...

  • Breaking the pain barrier. Machelska, Halina; Heppenstall, Paul A.; Stein, Chrisioph // Nature Medicine;Nov2003, Vol. 9 Issue 11, p1353 

    Focuses on effectiveness of the drug artemin in treating neuropathic pain in which even the slightest touch can hurt. Revelation that artemin reverses pain and neurochemical changes after the nerve injury in an animal model; Discussion of different causes of neuropathic pain; Information that...

  • Duloxetine, Pregabalin, and Duloxetine Plus Gabapentin for Diabetic Peripheral Neuropathic Pain Management in Patients With Inadequate Pain Response to Gabapentin: An Open-Label, Randomized, Noninferiority Comparison. Tanenberg, Robert J.; Irving, Gordon A.; Risser, Richard C.; Ahl, Jonna; Robinson, Michael J.; Skljarevski, Vladimir; Malcolm, Sandra K. // Mayo Clinic Proceedings;Jul2011, Vol. 86 Issue 7, p615 

    OBJECTIVE: To determine whether duloxetine is noninferior to (as good as) pregabalin in the treatment of pain associated with diabetic peripheral neuropathy. PATIENTS AND METHODS: We performed a 12-week, open-label study of patients with diabetic peripheral neuropathic pain who had been treated...

  • Medicinal marijuana found ineffective for relief of rheumatoid conditions.  // Nursing Standard;3/26/2014, Vol. 28 Issue 30, p18 

    The article discuses research reported in the article "The Dilemma of Medical Marijuana Use by Rheumatology Patients" by M. Fitzcharles et al., in a 2014 issue of "Arthritis Care & Research", which found that medical marijuana is ineffective for treating rheumatoid conditions.

  • Comment on "Short-Term Efficacy of Ultramicronized Palmitoylethanolamide in Peripheral Neuropathic Pain". Kriek, R. // Pain Research & Treatment;2014, p1 

    No abstract available.

  • Recognising and treating neuropathic pain. Morris, David // Independent Nurse;11/3/2008, p40 

    The article discusses the causes and management of neuropathic pain. Some of the causes of neuropathic pain includes the post-herpetic neuralgia, diabetic neuropathy, trigeminal neuralgia and nerve compression. Patients who experience the pain described it as burning, tingling, shooting or like...

  • National survey of pain clinics in Croatia: Organization and services. Fidahić, Mahir; Dogan, Katarina; Sapunar, Damir; Puljak, Livia // Acta Medica Academica;May2015, Vol. 44 Issue 1, p18 

    Objective. To analyze organization and therapeutic procedures administered in tertiary outpatient pain clinics in Croatia. Methods. Data about organization of pain clinics, its personnel, equipment, continuing medical education, therapeutic procedures, research activities and relations with...

  • THE RIGHT (AND WRONG) WAY TO TREAT PAIN. Wallis, Claudia; Cray, Dan; Daniels, Chris; Park, Alice; Sieger, Maggie // Time;2/28/2005, Vol. 165 Issue 9, p46 

    Discusses pain management. Concern of pain sufferers who use Vioxx at the drug's removal from the market; Decision of the U.S. Food and Drug Administration to let COX-2 family drugs, including Bextra and Celebrex, stay on the market; Belief of many doctors that depending on a pharmaceutical...

  • Nortriptyline, gabapentin, or both for neuropathic pain.  // Clinical Oncology Alert;Jan2010 Supplement, p1 

    The article discusses research on the efficacy of nortriptyline and gabapentin alone and in combination in treating neuropathic pain (NPN). It references a study by I. Gilron et al published in a 2009 issue of "Lancet." The study demonstrated that the combination of the two agents have achieved...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics